The Coghlan Group
The Coghlan Group provides a full range of clinical trial material management and centralized randomization services to companies around the world. Located in the Bastrop Business Park, the company was founded by experienced clinical trial professionals to provide the pharmaceutical research industry with a realizable source for the preparation, packaging/labeling, and randomization of clinical trial material.
In 2017 The Coghlan Group was acquired by UK-based Caligor Holdco, LLC. “Partnering with Caligor was the ideal opportunity for us,” stated Terry Coghlan, Chief Executive Officer, The Coghlan Group. “They bring specialized offerings supporting clinical trials with their expert commercial drug sourcing and supply services as well as providing managed global access programs to unlicensed medicines outside of the trial environment for patients in need.”
Caligor Holdco, LLC., announced today the acquisition of The Coghlan Group, a leading materials management service company for clinical trials. This strategic acquisition specifically adds deep domain expertise in packaging, labeling, distribution, storage and returns, and destruction services of pharmaceutical drugs, adding to Caligor's comprehensive set of clinical trial offerings for its global pharmaceutical and biotechnology clients. Caligor Holdco, LLC, purchased by Diversis Capital in April 2016, is a premier pharmaceutical and biotechnology services company specializing in the sourcing, distribution and storage of comparator drugs for clinical trials worldwide as well as a leading provider of unique and differentiated high touch unlicensed medicines for expanded access programs. The combined company will retain the Caligor Holdco, LLC name but will be rebranded Caligor Coghlan, pending regulatory approvals.
"We are excited by the acquisition of The Coghlan Group as part of Caligor's clinical services expansion plan as they bring a proven track record of global clinical packaging and labeling solutions to the world's leading pharmaceutical and biotechnology companies," said Ron Nayot, Managing Director, Diversis Capital LLC. "The Coghlan Group's culture of high touch service and a patient first mentality fits perfectly with Caligor's belief that we must go the extra mile to provide unparalleled services for our customers."
"Coghlan's world-class packaging and labeling capabilities are a perfect complement to Caligor's capabilities in commercial drug sourcing and supply, its own clinical secondary packaging and labeling operation, worldwide distribution and logistics, and global expanded access programs," said David N. Edwards, Chief Executive Officer, Caligor Holdco, LLC. "Going forward, Caligor Coghlan is well-positioned to become the leading clinical trial supply chain services provider, offering a diversified suite of services capable of delivering end-to-end solutions to our pharmaceutical and biotechnology partners."
The Coghlan Group supports clinical trials by providing a full range of trial material management to companies around the world. Founded by experienced clinical trial professionals, The Coghlan Group provides the pharmaceutical research industry with premier secondary packaging and labeling of clinical trial material, storage, distribution and final accountability and destruction of returned drugs.
Visit Markets Insider for the full article.
Bastrop, TX 78602